AMELX

Across TCGA pan-cancer cohorts, AMELX Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated AMELX data layer compared with 22 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher AMELX Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated AMELX expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

LUAD, LGG, and SKCM are the cancer types where AMELX Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.163	0.663	.012	12	view →
LGG	DFS	Median	All	0.089	0.845	<.001	6	view →
SKCM	OS	Median	III,IV	1.000	0.377	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

AMELX–LUAD (OS)

Open the LUAD breakdown →